M1 muscarinic acetylcholine receptor Inhibitors
1 drugsAbout M1 muscarinic acetylcholine receptor
The M1 muscarinic acetylcholine receptor (M1 mAChR) is a GPCR that mediates acetylcholine neurotransmission in the central nervous system. It influences cognitive functions like learning and memory.
M1 mAChR is a therapeutic target for neurological disorders, but currently lacks genetic evidence linking it to specific diseases.
COBENFY is the only FDA-approved drug targeting M1 mAChR, developed by Bristol-Myers Squibb as a small molecule for CNS indications. It was first approved in 2024.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Mania with only 1 trials.
Top M1 muscarinic acetylcholine receptor Drugs
Bristol-Myers Squibb is the only company with an approved drug targeting M1 mAChR.
Low competition presents an opportunity for new entrants, but also indicates potential challenges.
M1 muscarinic acetylcholine receptor Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets M1 muscarinic acetylcholine receptor, using small molecule modality.
Explore alternative modalities like antibodies or biologics to differentiate from existing therapies.
M1 muscarinic acetylcholine receptor Clinical Trials 31 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 8 | 4 | 0 | 4 | 100% |
| Phase 2 | 1 | 1 | 0 | 0 | 100% |
| Phase 3 | 12 | 7 | 1 | 4 | 88% |
| Phase 4 | 10 | 7 | 0 | 3 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
M1 muscarinic acetylcholine receptor Drug Approval Timeline (2024 - 2024)
The first and only drug was approved in 2024, representing a 1-year approval span.
Recent approval suggests renewed interest, but also early stage of market development.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (12 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 28 clinical trials targeting M1 muscarinic acetylcholine receptor.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities